⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17969121 | 0.81 | — | — | |
| SCHEMBL3069942 | 0.76 | — | — | |
| SCHEMBL3069943 | 0.76 | — | — | |
| SCHEMBL3292005 | 0.72 | — | — | |
| SCHEMBL669443 | 0.69 | — | — | |
| SCHEMBL452335 | 0.67 | — | — | |
| SCHEMBL450047 | 0.67 | — | — | |
| SCHEMBL206929 | 0.67 | AHR (0.37) | — | |
| SCHEMBL121647 | 0.67 | LMNA (0.43) | — | |
| SCHEMBL30334802 | 0.67 | LMNA (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0839144-B1 | PIPERAZINE DERIVATIVES AS THERAPEUTIC AGENTS | KNOLL GMBH (DE) | 2001-09-19 | — | — | EP | claimed |
| US-6114334-A | CENTRAL NERVOUS SYSTEM DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 2000-09-05 | — | — | US | claimed |
| EP-0839144-A1 | PIPERAZINE DERIVATIVES AS THERAPEUTIC AGENTS | Knoll AG (DE) | 1998-05-06 | — | — | EP | claimed |
| WO-1997003067-A1 | PIPERAZINE DERIVATIVES AS THERAPEUTIC AGENTS | KNOLL AKTIENGESELLSCHAFT (DE) | 1997-01-30 | — | — | WO | claimed |
| CN-108290838-B | Biaryl derivatives and drugs containing the same | 科研制药株式会社 | 2021-12-31 | — | — | CN | disclosed |
| WO-2019180176-A1 | COMPOSITION FOR THE TREATMENT OF SCHIZOPHRENIA AND/OR PSYCHOSIS | SPHERIUM BIOMED, S.L. (ES) | 2019-09-26 | — | — | WO | disclosed |
| EP-3194392-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Plexxikon, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016044067-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| EP-2970265-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014145051-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ZHANG JIAZHONG (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140045836-A1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVES AS HSP90 MODULATORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-02-13 | — | — | US | disclosed |
| US-8580783-B2 | [1,2,4]triazolo [1,5-c]pyrimidine derivatives as Hsp90 modulators | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-12 | — | — | US | disclosed |
| EP-1474140-B1 | 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2007-11-21 | — | — | EP | disclosed |
| WO-2005097113-A2 | 5-HT2B RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2005-10-20 | — | — | WO | disclosed |
| US-20050176791-A1 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
| US-20040010022-A1 | 5-HT2B receptor antagonists | ASTERAND, INC. | 2004-01-15 | — | — | US | disclosed |
| EP-0839144-B1 | PIPERAZINE DERIVATIVES AS THERAPEUTIC AGENTS | KNOLL GMBH (DE) | 2001-09-19 | — | — | EP | disclosed |
| US-6114334-A | CENTRAL NERVOUS SYSTEM DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 2000-09-05 | — | — | US | disclosed |
| EP-0839144-A1 | PIPERAZINE DERIVATIVES AS THERAPEUTIC AGENTS | Knoll AG (DE) | 1998-05-06 | — | — | EP | disclosed |
| WO-1997003067-A1 | PIPERAZINE DERIVATIVES AS THERAPEUTIC AGENTS | KNOLL AKTIENGESELLSCHAFT (DE) | 1997-01-30 | — | — | WO | disclosed |